# Trifluridine-Tipiracil

## Lonsurf 20mg

| 藥物代碼 | OLONS |
| :--- | :--- |
| 適應症 | Metastatic colorectal cancer in adults |
| 副作用 | &gt;10%:Fatigue \(52%\), Nausea \(37% to 48%\), decreased appetite \(34% to 39%\), diarrhea \(23% to 32%\), vomiting \(25% to 28%\), abdominal pain \(21%\), Anemia \(63% to 77%; grades 3/4: 18% to 19%\), neutropenia \(66% to 67%; grades 3/4: 38%;\), thrombocytopenia \(34% to 42%; grades 3/4: 5% to 6%\), febrile neutropenia \(grades 3/4: 3%\), Infection \(23% to 27%\), Asthenia \(?52%\), Fever \(19%\)1% to 10%:Pulmonary embolism \(2% to 3%\), Alopecia \(7%\), Stomatitis \(8%; grades 3/4: &lt;1%\), dysgeusia \(7%\)&lt;1%: postmarketing, and/or case reports: Interstitial pulmonary disease |
| 禁忌 | There are no contraindications listed in the manufacturer's labeling. |
| 藥物保存方式 | 儲存於 25℃以下。 |
| 用法用量 | Oral: 35 mg/m2 \(based on the trifluridine component\) twice daily on days 1 to 5 and days 8 to 12 of a 28-day cycle \(maximum per dose: trifluridine 80 mg\); continue until disease progression or unacceptable toxicity. The manufacturer recommends rounding each dose to the nearest 5 mg increment. |
| 肝功能異常 | 需 調 整 劑 量  Moderate impairment \(total bilirubin &gt;1.5 to 3 times ULN and any AST\) or severe impairment \(total bilirubin &gt;3 times ULN and any AST\): Do not initiate therapy. |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 不可使用 |
| 孕期用藥建議 | N/A |
| 附帶說明 | Micromedex: Fetal risk cannot be ruled out. |
| 哺乳期用藥建議 | N/A |
| 附帶說明 | Micromedex: Infant risk cannot be ruled out. |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

